Business Context and Reporting Period
This Form 6-K filing by GlaxoSmithKline plc (GSK) covers the period ending October 3, 2016. The report serves as a notification to the market regarding the Company's total voting rights and capital structure in conformity with Disclosure and Transparency Rule 5.6.1R.
Key Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. This document is strictly a capital structure notification and does not contain financial performance data.
Material Changes
The filing details the Company's issued share capital as of September 30, 2016:
- Total Issued Ordinary Shares: 5,367,261,326 (25p each).
- Shares held in Treasury: 491,505,950.
- Total Voting Rights: 4,875,755,376.
The filing does not explicitly state material changes compared to a prior comparable period, though it provides the current denominator for shareholder notification calculations.
Guidance, Outlook, and Risks
The filing text does not provide a clear value for guidance, outlook, management commentary, risks, contingencies, or unusual items. The document is limited to statutory capital disclosure.
Key Facts for Investor Verification
- Verify the total number of voting rights (4,875,755,376) against the latest 20-F annual report to confirm the denominator for disclosure thresholds.
- Confirm the number of shares held in Treasury (491,505,950) to understand the difference between issued capital and voting capital.
- Note that this filing does not contain operational or financial performance updates; investors should refer to other filings for earnings data.